Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors.
about
Profile of pazopanib and its potential in the treatment of epithelial ovarian cancerMechanism-based inactivation of CYP450 enzymes: a case study of lapatinibSystemic therapy for selected skull base sarcomas: Chondrosarcoma, chordoma, giant cell tumour and solitary fibrous tumour/hemangiopericytoma.Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors.Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies.Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations.Preclinical Modeling of Tumor Growth and Angiogenesis Inhibition to Describe Pazopanib Clinical Effects in Renal Cell Carcinoma.Retrospective analysis of patients with rare-site and metastatic giant cell tumor.Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy.Pazopanib for the treatment of renal cell carcinoma.Combine and conquer: challenges for targeted therapy combinations in early phase trials.Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.Cyberknife stereotactic radiosurgery and denosumab for giant cell tumour of the skull base: Case report.Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors.
P2860
Q27011840-EDCA0BC3-0AAB-4755-A0BB-A8663BC68E7FQ28080497-E88DAEBF-AAF1-4D74-8933-291E3E5C751AQ33276109-06613ECF-0064-4AFE-9F93-3656E0ABE6EEQ33412909-216A0DC2-4A2B-4820-B238-5583DD233A4FQ33683001-F4EFC606-83BD-40CB-8E68-8FF704BCA72AQ35023711-676E658C-697D-43B7-8D68-BC3D32B5B8B5Q36473115-E3B93794-3D70-49BD-AB26-09D70A5FEB93Q37309465-DDAE2F25-3E5C-47A1-BEB9-2BA015429E38Q38193533-42E1E9EA-3CCC-4F6A-840C-F978007FB704Q38400468-ABAFC1B2-9217-44DA-9D3D-667278E591C3Q38734451-737D172D-A514-413E-B1AD-2F57C637C075Q38936104-C1DF7C2E-CF89-4CCC-9957-FB98F9845196Q50202204-F0E64F74-DA6D-42A5-9F55-3BBA837D0640Q51012619-9530F5C8-5F09-4ED4-A86A-C2B0CF1FC91FQ54256816-C25B494E-9909-4557-BBDA-9C6B46A78BA5
P2860
Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Phase I and pharmacokinetic st ...... ts with advanced solid tumors.
@ast
Phase I and pharmacokinetic st ...... ts with advanced solid tumors.
@en
Phase I and pharmacokinetic st ...... ts with advanced solid tumors.
@nl
type
label
Phase I and pharmacokinetic st ...... ts with advanced solid tumors.
@ast
Phase I and pharmacokinetic st ...... ts with advanced solid tumors.
@en
Phase I and pharmacokinetic st ...... ts with advanced solid tumors.
@nl
prefLabel
Phase I and pharmacokinetic st ...... ts with advanced solid tumors.
@ast
Phase I and pharmacokinetic st ...... ts with advanced solid tumors.
@en
Phase I and pharmacokinetic st ...... ts with advanced solid tumors.
@nl
P2093
P2860
P1476
Phase I and pharmacokinetic st ...... ts with advanced solid tumors.
@en
P2093
A Benjamin Suttle
Herbert I Hurwitz
Jaap Verweij
Jeffrey Hodge
Lini N Pandite
Maja J A de Jonge
Paul Hamberg
Shawna Savage
Thangam Arumugham
P2860
P2888
P304
P356
10.1007/S10637-012-9885-8
P577
2012-10-06T00:00:00Z
P5875
P6179
1020683854